SU596165A3 - Способ получени имидазолидинов - Google Patents

Способ получени имидазолидинов

Info

Publication number
SU596165A3
SU596165A3 SU762414002A SU2414002A SU596165A3 SU 596165 A3 SU596165 A3 SU 596165A3 SU 762414002 A SU762414002 A SU 762414002A SU 2414002 A SU2414002 A SU 2414002A SU 596165 A3 SU596165 A3 SU 596165A3
Authority
SU
USSR - Soviet Union
Prior art keywords
preparing
imidazolidine
solvent
trifluoromethyl
imidaealidines
Prior art date
Application number
SU762414002A
Other languages
English (en)
Russian (ru)
Inventor
Перронне Жак
Жиро Пьер
Бонне Клод
Original Assignee
Руссель-Юклаф (Фирма)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Руссель-Юклаф (Фирма) filed Critical Руссель-Юклаф (Фирма)
Application granted granted Critical
Publication of SU596165A3 publication Critical patent/SU596165A3/ru
Priority to MD94-0279A priority Critical patent/MD246C2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Electromechanical Clocks (AREA)
SU762414002A 1975-10-29 1976-10-21 Способ получени имидазолидинов SU596165A3 (ru)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MD94-0279A MD246C2 (ro) 1975-10-29 1994-09-08 Procedeu de obţinere a imidazolidinelor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7533084A FR2329276A1 (fr) 1975-10-29 1975-10-29 Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant

Publications (1)

Publication Number Publication Date
SU596165A3 true SU596165A3 (ru) 1978-02-28

Family

ID=9161795

Family Applications (1)

Application Number Title Priority Date Filing Date
SU762414002A SU596165A3 (ru) 1975-10-29 1976-10-21 Способ получени имидазолидинов

Country Status (18)

Country Link
US (1) US4097578A (US07655688-20100202-C00086.png)
JP (1) JPS6011701B2 (US07655688-20100202-C00086.png)
AU (1) AU500542B2 (US07655688-20100202-C00086.png)
BE (1) BE847742A (US07655688-20100202-C00086.png)
BG (1) BG60533B2 (US07655688-20100202-C00086.png)
CA (1) CA1086751A (US07655688-20100202-C00086.png)
CH (1) CH599164A5 (US07655688-20100202-C00086.png)
DE (1) DE2649925C2 (US07655688-20100202-C00086.png)
DK (1) DK152125C (US07655688-20100202-C00086.png)
ES (1) ES452746A1 (US07655688-20100202-C00086.png)
FR (1) FR2329276A1 (US07655688-20100202-C00086.png)
GB (1) GB1518444A (US07655688-20100202-C00086.png)
GE (1) GEP19970948B (US07655688-20100202-C00086.png)
IE (1) IE43875B1 (US07655688-20100202-C00086.png)
LU (2) LU76085A1 (US07655688-20100202-C00086.png)
NL (2) NL187102C (US07655688-20100202-C00086.png)
SE (1) SE430502B (US07655688-20100202-C00086.png)
SU (1) SU596165A3 (US07655688-20100202-C00086.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2497812C2 (ru) * 2009-04-17 2013-11-10 Ипсен Фарма С.А.С. Производные имидазолидин-2,4-диона и их применение в качестве лекарственного средства против рака

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC1220A1 (fr) * 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
CA1138334A (en) * 1977-10-28 1982-12-28 Karl Bernauer Pharmaceutical preparations containing certain urea derivatives
FI801184A (fi) * 1979-04-24 1980-10-25 Hoffmann La Roche Foerfarande foer framstaellning av imidazolidinderivat
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
AU594309B2 (en) * 1984-08-02 1990-03-08 Fernand Labrie Pharmaceutical composition for combination therapy of hormonedependent cancers
IT1214735B (it) * 1986-11-04 1990-01-18 Roussel Maestretti Spa Impiego di 1-(3'-trifluorometil 4'nitrofenil) 4,4-dimetilimidazolin2,5-dione per il trattamento di cancri ormonodipendenti diverso da quello della prostata
US5084472A (en) * 1986-11-04 1992-01-28 Roussel Application of 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4'-dimethylimidazoline 2,5-dione in the treatment of hormone-dependent cancers other than that of the prostate
FR2619381B1 (fr) * 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
FR2656302B1 (fr) * 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
USRE35956E (en) * 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2685328B1 (fr) * 1991-12-20 1995-12-01 Rhone Poulenc Agrochimie Derives de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
US6002016A (en) * 1991-12-20 1999-12-14 Rhone-Poulenc Agrochimie Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones
FR2706456B1 (fr) * 1993-06-18 1996-06-28 Rhone Poulenc Agrochimie Dérivés optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US6008370A (en) * 1992-11-25 1999-12-28 Rhone-Poulenc Agrochimie Fungicidal-2-alkoxy/haloalkoxy-1-(mono- or disubstituted)amino-4,4-disubstituted-2-imidazolin-5-ones
FR2724169B1 (fr) * 1994-09-06 1997-01-03 Roussel Uclaf Nouvelles phenylimidazolidines eventuellement substituees, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) * 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2725206B1 (fr) * 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
IL152719A0 (en) * 2000-06-28 2003-06-24 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
EP1854798A3 (en) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7015253B2 (en) * 2001-07-10 2006-03-21 American Medical Systems, Inc. Regimen for treating prostate tissue and surgical kit for use in the regimen
AU2002364082A1 (en) * 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
US7354933B2 (en) * 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CA2536349A1 (en) 2003-08-22 2005-03-03 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
EP2299266A1 (en) * 2003-12-19 2011-03-23 The Regents of the University of California Methods and materials for assessing prostate cancer therapies
AU2005232526B2 (en) * 2004-02-24 2011-06-23 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
WO2005090282A1 (en) 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
JP5031568B2 (ja) * 2004-09-10 2012-09-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドロゲン受容体モジュレーター（ｓａｒｍｓ）としての新規なイミダゾリジン−２−オン誘導体
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
PT2444085E (pt) 2005-05-13 2015-06-11 Univ California Compostos de diaril-hidantoínas como antagonistas do recetor androgénio para tratamento de cancro
CA2598216C (en) 2005-06-17 2014-04-08 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP2656842B1 (en) 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
EP3020706A1 (en) 2006-03-29 2016-05-18 The Regents Of The University Of California Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
EP2099375B1 (en) 2007-01-02 2014-09-24 AquaBeam LLC Minimally invasive devices for the treatment of prostate diseases
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
CA2966280A1 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
WO2009111736A1 (en) 2008-03-06 2009-09-11 Aquabeam Llc Tissue ablation and cautery with optical energy carried in fluid stream
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
WO2014127242A2 (en) 2013-02-14 2014-08-21 Procept Biorobotics Corporation Aquablation aquabeam eye surgery methods and apparatus
PT3124481T (pt) 2010-02-16 2018-06-18 Aragon Pharmaceuticals Inc Moduladores do receptor de androgénios e suas utilizações
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
JP6080872B2 (ja) 2012-02-29 2017-02-15 プロセプト バイオロボティクス コーポレイション 自動化された画像誘導組織切除および治療
EA030128B1 (ru) 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US10011874B2 (en) 2013-02-25 2018-07-03 Novartis Ag Androgen receptor mutation
CN109965976B (zh) 2013-09-06 2022-05-31 普罗赛普特生物机器人公司 利用致脱脉冲的用于消融组织的装置
BR112016031037B1 (pt) 2014-06-30 2023-02-07 Procept Biorobotics Corporation Aparelho para ablação de tecido vascular
JP2017532095A (ja) 2014-09-05 2017-11-02 プロセプト バイオロボティクス コーポレイション 標的器官画像の処理マッピングと一体化された医師制御組織切除
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3500310A1 (en) 2016-08-20 2019-06-26 FTF Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
CN107216290B (zh) * 2017-06-12 2021-03-16 陕西科技大学 一种3-丁基-5,5-二甲基海因咪唑季铵盐及其制备方法
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB997037A (en) * 1962-03-19 1965-06-30 Ici Ltd New hydrantoin derivatives
JPS4920973B1 (US07655688-20100202-C00086.png) * 1970-05-28 1974-05-29
JPS5136332B1 (US07655688-20100202-C00086.png) * 1970-12-09 1976-10-07
IL45459A (en) * 1973-09-03 1978-01-31 Ciba Geigy Ag 1-(dichlorofluoromethylthio)-3-phenyl-imidazolidine-2,4-dione derivatives their preparation and their use as bactericides and fungicides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2497812C2 (ru) * 2009-04-17 2013-11-10 Ипсен Фарма С.А.С. Производные имидазолидин-2,4-диона и их применение в качестве лекарственного средства против рака
US8710091B2 (en) 2009-04-17 2014-04-29 Ipsen Pharma S.A.S. Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug

Also Published As

Publication number Publication date
GB1518444A (en) 1978-07-19
JPS6011701B2 (ja) 1985-03-27
DK487476A (da) 1977-04-30
LU88282I2 (fr) 1994-05-04
GEP19970948B (en) 1997-04-18
IE43875B1 (en) 1981-06-17
LU76085A1 (US07655688-20100202-C00086.png) 1977-05-31
NL187102B (nl) 1991-01-02
FR2329276B1 (US07655688-20100202-C00086.png) 1979-09-14
FR2329276A1 (fr) 1977-05-27
SE7610859L (sv) 1977-04-30
BG60533B2 (bg) 1995-07-28
SE430502B (sv) 1983-11-21
NL187102C (nl) 1991-06-03
AU500542B2 (en) 1979-05-24
NL930079I2 (nl) 1993-10-01
ES452746A1 (es) 1977-10-01
CH599164A5 (US07655688-20100202-C00086.png) 1978-05-12
DE2649925C2 (de) 1986-08-28
BE847742A (fr) 1977-04-28
NL7611576A (nl) 1977-05-03
DE2649925A1 (de) 1977-05-12
US4097578A (en) 1978-06-27
DK152125B (da) 1988-02-01
CA1086751A (fr) 1980-09-30
DK152125C (da) 1988-06-20
AU1909576A (en) 1978-05-04
JPS5257176A (en) 1977-05-11
IE43875L (en) 1977-04-29
NL930079I1 (nl) 1993-09-16

Similar Documents

Publication Publication Date Title
SU596165A3 (ru) Способ получени имидазолидинов
Butler et al. The Formation of Linear Polymers from Diene Monomers by a Cyclic Polymerization Mechanism. I. The Structure of Poly-(diallylammonium Halides) 1, 2
ATE1192T1 (de) Verfahren zur herstellung von beta-lactam-derivaten, die so erhaltenen neuen derivate sowie diese derivate enthaltende pharmazeutische zusammensetzungen.
US4093653A (en) Process for the preparation of optically active phenyl glycine amide
DE2322576A1 (de) Antibiotische derivate und verfahren zu deren herstellung
US3901915A (en) Optical resolution of organic carboxylic acids
IE40626B1 (en) Benzophenone derivatives and their production
SU612626A3 (ru) Способ получени 3-(3,5-дихлорфенил)гидантоина
ATE43585T1 (de) Neue imidazolylverbindungen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
SU530022A1 (ru) Способ получени гидразидов аминокислот
CH473821A (de) Verfahren zur Herstellung von Iminodibenzyl-Derivaten
SU598871A1 (ru) Способ получени гидрохлорида метиламиноацетопирокатехина
US2785183A (en) N [4-aminopyrrolyl-2-carbonyl] amino acids
SU487886A1 (ru) Способ получени 1- -хлоргексилкарбамоилбензимидазолин-2-карбаматов
SU1245573A1 (ru) Способ получени 5-алкил- @ -карбэтоксиметил-2-пирролидонов
DE3101960A1 (de) "basisch substituierte anthranilsaeuren, verfahren zu ihrer herstellung und ihre verwendung"
SU489315A3 (ru) Способ получени производных фенилгуанидина
EP0025859A3 (de) Verfahren zur Herstellung von 1,2,4-Triazolen
SE408414B (sv) Saett att framstaella n,n'-diklorisoftalsyraamid genom klorering av isoftalsyraamid
EP0051816A1 (de) Basisch substituierte 5-Phenyltetrazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Heilmittel
SU979339A1 (ru) Способ получени 2-амино-3,4-дициано-1,5-замещенных пирролов
SU478833A1 (ru) Способ получени производных тиено -(3,2-в)-пиррола
SU667130A3 (ru) Способ получени соли лизина и -метил-(изопропил-2-инданил-5) уксусной кислоты
SU479768A1 (ru) Способ получени производных пиримидина
AT219025B (de) Verfahren zur Herstellung von neuen (2-Äthyl-3,3-diphenyl-propanol-3)- und [2-Äthyl-3,3-diphenyl-propen-(2)-yl]-aminen und deren Salzen